



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 October 2010
EMA/655737/2010
Committee for medicinal products for human use (CHMP)

Summary of opinion¹ (post authorisation)

Sutent sunitinib

On 21 October 2010 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Sutent. The marketing authorisation holder for this medicinal product is Pfizer Ltd. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication as follows:

"Pancreatic neuroendocrine tumours (pNET)

Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with sunitinib as first-line treatment is limited (see section 5.1)."

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Sutent will be as follows²:

"Gastrointestinal stromal tumour (GIST)

Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.

Metastatic renal cell carcinoma (MRCC)

¹ Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended indication.



Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.

Pancreatic neuroendocrine tumours (pNET)

Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.

Experience with sunitinib as first-line treatment is limited (see section 5.1)."